Tips for Summer Safety
Many people love the warm sun, beaches, and gardens, but along with those beautiful summer days comes the threat of sun damage. What does this mean for GIST patients?
Examining Kidney Toxicities of Sunitinib and Imatinib in Long-Term GIST Therapy
On September 19, 2016 the Life Raft Group was pleased to have Dr. Benjamin D. Humphreys, Chief of the Division of Nephrology at Washington University in St. Louis School of Medicine, share his knowledge [...]
The Heart of the Matter: Cardiac Health for GIST Patients
The heart is at the center of the cardiovascular system, the main function of which is to pump blood throughout the body, providing tissue and organs with the oxygen and nutrients they need. To [...]
Cancer Survivors and Heart Health
Cancer patients are surviving longer thanks to breakthrough treatments like targeted therapies. With the additional longevity, however, is the responsibility to consider other health issues that may manifest, either due to treatments such as [...]
Clinical Registry Study Planned by ASCO
American Society of Clinical Oncology (ASCO) is planning its first-ever clinical registry study, the Targeted Agent and Profiling Utilization Registry (TAPUR). ASCO plans should increase patient access to off-label drugs and match patients with [...]
Pfizer Releases New Dosage for Sutent Patients
Sutent 37.5 mg Ease of use and lower costs may be on the horizon for Sutent patients who are currently on a 37.5 milligram prescription. Available now, Pfizer has released a new [...]
Recent Study Discusses Alternative Schedules for Sutent
A recent study published in Oncology Letters, discusses the importance of effective therapy management of sunitinib (Sutent)
Our Decision to Enter Hospice
I’ve been thinking a lot about writing this article. The last thing I want to do is cause worry or pain to anyone reading this. Then I thought of all the people who could possibly benefit in the future from knowing ahead of time what we didn’t know at the time we needed to know it.
Stivarga becomes first FDA-approved third-line drug treatment for GIST
The Food and Drug Administration, in a much-anticipated announcement for Gastrointestinal Stromal Tumor patients, approved Bayer Pharmaceutical’s drug, Stivarga, for use as a third-line treatment for advanced GIST in February.